Research programme: solid tumour therapeutics - IncuronAlternative Names: CBL 0175; CBLC100 series; Curaxins
Latest Information Update: 09 Mar 2015
At a glance
- Originator Cleveland BioLabs
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; DNA intercalators; NF-kappa B inhibitors; SSRP1 protein inhibitors; Tumour suppressor protein p53 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours